trial

A Comparison of Long-acting Injectable Medications for Schizophrenia

NCTId NCT01136772
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 311 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2013-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
311 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-03
Primary completion
2013-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
HaloperidolPaliperidone

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Duke UniversityCollaborator
University of North Carolina, Chapel HillCollaborator

Investigators

2
Scott Stroup, MD, MPHPrincipal Investigator
Joseph P. McEvoy, MDPrincipal Investigator

Sites

22 total
Palo Alto, United StatesNew Haven, United StatesMiami, United StatesAugusta, United StatesIowa City, United StatesWichita, United StatesGlen Burnie, United StatesDetroit, United StatesLansing, United StatesKansas City, United StatesOmaha, United StatesNew York, United States

Facts & assertions

4 sourced
Enrollment
311
Phase
PHASE4
Primary Completion Date
2013-07
Status
COMPLETED
relationships
The graph out of here
drug
Haloperidol
drug
Paliperidone
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
Duke University
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Scott Stroup, MD, MPH
person
Joseph P. McEvoy, MD
person